Objective:To investigate the feasibility of using a colonic mucosa graft(CMG)for ureteral reconstruction and assess histological changes following the engrafted CMG in Beagles.Methods:Nine male Beagle dogs were random...Objective:To investigate the feasibility of using a colonic mucosa graft(CMG)for ureteral reconstruction and assess histological changes following the engrafted CMG in Beagles.Methods:Nine male Beagle dogs were randomly assigned to groups Ⅰ,Ⅱ,and Ⅲ(n=3).Resection of half of the ureteral wall caused a ventral ureteral defect.Ureteral defects with lengths of 3 cm,5 cm,and 10 cm were created in these groups,respectively.The CMG was harvested and used to repair the ureteral defects in an onlay fashion.After functional evaluation of the reconstructed ureter using CT urography at 3 months,6 months,and 12 months postoperatively,one Beagle from each group was euthanized using air embolization.Ureteral diameter measurements and the CMG shrinkage rate calculations were performed.Histological analysis was conducted to assess changes in the engrafted CMG.Results:All animals had no postoperative complications.CT urography showed normal renal function and a wide caliber ureter with no stricture or leakage.The ureteral diameter reconstructed by the CMG was larger than that of the proximal or distal normal ureter(p<0.05).The mean shrinkage rate of the CMG ranged from 11% to 14%.From 3 months to 12 months postoperatively,the colonic mucosal epithelium gradually underwent metaplasia into urothelium,and smooth muscle and neovascularization gradually developed beneath the mucosa.展开更多
Previous studies have sought to classify bladder cancer(BLCA)into different molecular subtypes to understand its pathogenic pathways and uncover specific treatments.1 These subtypes,often based on genetic,transcriptom...Previous studies have sought to classify bladder cancer(BLCA)into different molecular subtypes to understand its pathogenic pathways and uncover specific treatments.1 These subtypes,often based on genetic,transcriptomic,or proteomic profiles,aim to stratify patients for precision medicine and improve therapeutic outcomes.Despite these efforts,such classifications have rarely been applied in clinical practice due to challenges in standardization,reproducibility,and limited translational studies validating their utility.1 The treatment of BLCA predominantly relies on surgery,often combined with chemotherapy,immunotherapy,targeted therapy,or antibody-drug conjugates.Radical cystectomy remains the cornerstone for muscle-invasive bladder cancer(MIBC),while transurethral resection and intravesical therapy are common for non-muscle-invasive bladder cancer(NMIBC).2 However,the choice of its treatment modality still depends specifically on whether the disease is NMIBC or MIBC,rather than on the various molecular subtype classifications.3 Bridging the gap between molecular research and clinical application remains a significant challenge,highlighting the need for robust biomarker validation and the development of treatment algorithms that incorporate these subtypes to better guide personalized therapy.展开更多
基金funded by the grant from Zhongnan Hospital of Wuhan University(CN,Grant No.rcyj20230102 to Li B)the grant from Wuhan Union Hospital(CN,Grant No.2021xhlcyj11 to Li B).
文摘Objective:To investigate the feasibility of using a colonic mucosa graft(CMG)for ureteral reconstruction and assess histological changes following the engrafted CMG in Beagles.Methods:Nine male Beagle dogs were randomly assigned to groups Ⅰ,Ⅱ,and Ⅲ(n=3).Resection of half of the ureteral wall caused a ventral ureteral defect.Ureteral defects with lengths of 3 cm,5 cm,and 10 cm were created in these groups,respectively.The CMG was harvested and used to repair the ureteral defects in an onlay fashion.After functional evaluation of the reconstructed ureter using CT urography at 3 months,6 months,and 12 months postoperatively,one Beagle from each group was euthanized using air embolization.Ureteral diameter measurements and the CMG shrinkage rate calculations were performed.Histological analysis was conducted to assess changes in the engrafted CMG.Results:All animals had no postoperative complications.CT urography showed normal renal function and a wide caliber ureter with no stricture or leakage.The ureteral diameter reconstructed by the CMG was larger than that of the proximal or distal normal ureter(p<0.05).The mean shrinkage rate of the CMG ranged from 11% to 14%.From 3 months to 12 months postoperatively,the colonic mucosal epithelium gradually underwent metaplasia into urothelium,and smooth muscle and neovascularization gradually developed beneath the mucosa.
基金supported by the National Natural Science Foundation of China(No.82273065)Fundamental Research Funds for the Central Universities(China)(No.2042022dx0003)+1 种基金Research Fund of Zhongnan Hospital of Wuhan University(Wuhan,China)(No.YYXKNLJS2024001,PTPP2024001)The funders played no role in the study design,data collection and analysis,decision to publish,or preparation of the manuscript.
文摘Previous studies have sought to classify bladder cancer(BLCA)into different molecular subtypes to understand its pathogenic pathways and uncover specific treatments.1 These subtypes,often based on genetic,transcriptomic,or proteomic profiles,aim to stratify patients for precision medicine and improve therapeutic outcomes.Despite these efforts,such classifications have rarely been applied in clinical practice due to challenges in standardization,reproducibility,and limited translational studies validating their utility.1 The treatment of BLCA predominantly relies on surgery,often combined with chemotherapy,immunotherapy,targeted therapy,or antibody-drug conjugates.Radical cystectomy remains the cornerstone for muscle-invasive bladder cancer(MIBC),while transurethral resection and intravesical therapy are common for non-muscle-invasive bladder cancer(NMIBC).2 However,the choice of its treatment modality still depends specifically on whether the disease is NMIBC or MIBC,rather than on the various molecular subtype classifications.3 Bridging the gap between molecular research and clinical application remains a significant challenge,highlighting the need for robust biomarker validation and the development of treatment algorithms that incorporate these subtypes to better guide personalized therapy.
